Top

Published in:

01-09-2019 | Prostate Cancer | Urology - Original Paper

Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy

Authors: Shulin Wu, Sharron X. Lin, Min Lu, Alexander O. Subtelny, Zongwei Wang, Douglas M. Dahl, Aria F. Olumi, Chin-Lee Wu

Published in: International Urology and Nephrology | Issue 9/2019

Abstract

Objective

To investigate the oncological impact of incidental prostate cancer (iPCa) found during radical cystoprostatectomy (RCP) on overall survival (OS) prognosis of urothelial carcinoma of the bladder (BCa).

Patients and methods

A total of 122 RCP cases resected between 2002 and 2012 at our center were included for study. Survival of BCa patient was compared using the Kaplan–Meier method and the log-rank test. Cox proportional hazards regression models were used to analyze the impact of iPCa on the 5-year overall mortality of BCa patients after RCP.

Results

Among the 122 BCa cases that underwent RCP, 38 cases (31.1%) had iPCa, in which, 17 cases (44.7%) were identified as clinically significant iPCa (csPCa). BCa patients with iPCa were older (71 vs 64 years, p = 0.004) and had higher preoperative PSA level (3.1 ng/mL vs 1.4 ng/mL, p = 0.017) when compared to those without iPCa. Cases with iPCa showed a more favorable 5-year OS than cases without iPCa, although this difference did not reach statistical significance (p = 0.219). When excluding the higher risk cases with Gleason score (GS) ≥ 4 + 3 and/or preoperative PSA > 10 ng/mL, BCa patients with iPCa showed a significantly longer OS than cases without iPCa on univariate analysis (p = 0.044), but not on multivariate analysis (p = 0.125).

Conclusion

Our results demonstrated that the frequent findings of low-risk iPCa in BCa patients could indicate the potential possibility of shared pathogenesis pathways between iPCa and BCa. Future study with a larger cohort is warranted to validate this result.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 CrossRefPubMed

Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder C (2013) ICUD-EAU International consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63(1):45–57. https://doi.org/10.1016/j.eururo.2012.08.009 CrossRefPubMed

Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Stenzl A, Gakis G (2017) Clinicopathological features and prognostic value of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: a systematic review and meta-analysis of 13,140 patients. J Urol 197(2):385–390. https://doi.org/10.1016/j.juro.2016.08.088 CrossRefPubMed

Wolters T, Montironi R, Mazzucchelli R, Scarpelli M, Roobol MJ, van den Bergh RC, van Leeuwen PJ, Hoedemaeker RF, van Leenders GJ, Schroder FH, van der Kwast TH (2012) Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate 72(1):108–115. https://doi.org/10.1002/pros.21415 CrossRefPubMed

Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M, Raspollini MR, Montironi R (2017) Concomitant bladder cancer and prostate cancer: challenges and controversies. Nat Rev Urol 14(10):620–629. https://doi.org/10.1038/nrurol.2017.124 CrossRefPubMed

Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368–374CrossRefPubMed

Buse S, Hofner T, Muller SC, Hermann E, Wieland WF, May M, Stief CG, Bastian PJ, Hohenfellner M, Haferkamp A (2013) Characterization and risk stratification of prostate cancer in patients undergoing radical cystoprostatectomy. Int J Urol 20(9):866–871. https://doi.org/10.1111/iju.12073 CrossRefPubMed

Thomas C, Giesswein A, Hainz M, Stein R, Rubenwolf P, Roos FC, Neisius A, Nestler S, Hampel C, Jager W, Wiesner C, Thuroff JW (2015) Concomitant Gleason Score %3e/= 7 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy. Int Urol Nephrol 47(11):1789–1796. https://doi.org/10.1007/s11255-015-1110-1 CrossRefPubMed

Gakis G, Rink M, Fritsche HM, Graefen M, Schubert T, Hassan F, Chun FK, Brummeisl W, Fisch M, Burger M, Stenzl A, Renninger M (2016) Prognostic significance of incidental prostate cancer at radical cystoprostatectomy for bladder cancer. Urol Int 97(1):42–48. https://doi.org/10.1159/000443239 CrossRefPubMed

10.

Sruogis A, Ulys A, Smailyte G, Kardelis Z, Kulboka A, Anglickiene G, Samalavicius N, Anglickis M (2012) Incidentally found prostate cancer and influence on overall survival after radical cystoprostatectomy. Prostate Cancer 2012:690210. https://doi.org/10.1155/2012/690210 CrossRefPubMedPubMedCentral

11.

Malte R, Kluth LA, Kaushik D, Boorjian SA, Abufaraj M, Foerster B, Rink M, Gust K, Roghmann F, Noldus J, Vordos D, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Karakiewicz PI, Roupret M, Briganti A, Scherr DS, Shariat SF, Seebacher V (2017) Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. Eur J Surg Oncol 43(11):2193–2199. https://doi.org/10.1016/j.ejso.2017.08.013 CrossRefPubMed

12.

Kaelberer JB, O'Donnell MA, Mitchell DL, Snow AN, Mott SL, Buatti JM, Smith MC, Watkins JM (2016) Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival. Prostate Int 4(3):107–112. https://doi.org/10.1016/j.prnil.2016.06.002 CrossRefPubMedPubMedCentral

13.

Cho IC, Kim JE, Kim SH, Joung JY, Seo HK, Chung J, Park WS, Lee KH (2015) Oncologic aspects of long-term followed incidental prostate cancer detected by cystoprostatectomy in Korean patients. Prostate Int 3(2):56–61. https://doi.org/10.1016/j.prnil.2015.03.006 CrossRefPubMedPubMedCentral

14.

Pan J, Xue W, Sha J, Yang H, Xu F, Xuan H, Li D, Huang Y (2014) Incidental prostate cancer at the time of cystectomy: the incidence and clinicopathological features in Chinese patients. PLoS ONE 9(4):e94490. https://doi.org/10.1371/journal.pone.0094490 CrossRefPubMedPubMedCentral

15.

Moschini M, Shariat SF, Freschi M, Soria F, Abufaraj M, Gandaglia G, Dell'Oglio P, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R (2017) Impact of prostate involvement on outcomes in patients treated with radical cystoprostatectomy for bladder cancer. Urol Int 98(3):290–297. https://doi.org/10.1159/000454736 CrossRefPubMed

16.

Singh A, Kinoshita Y, Rovito PM Jr, Landas S, Silberstein J, Nsouli I, Wang CY, Haas GP (2008) Higher than expected association of clinical prostate and bladder cancers. J Urol 179(5 Suppl):S2–5. https://doi.org/10.1016/j.juro.2008.03.130 CrossRefPubMed

17.

Gakis G, Stenzl A, Renninger M (2013) Evolution of the concept of androgen-sensitive bladder cancer. Scand J Urol 47(3):173–178. https://doi.org/10.3109/00365599.2012.756929 CrossRefPubMed

18.

Wu S, Ye J, Wang Z, Lin SX, Lu M, Liang Y, Zhu X, Olumi AF, Zhong WD, Wu CL (2018) Expression of aromatase in tumor related stroma is associated with human bladder cancer progression. Cancer Biol Ther 19(3):175–180. https://doi.org/10.1080/15384047.2017.1414762 CrossRefPubMedPubMedCentral

19.

Chen CC, Huang CP, Tsai YT, Hseih TF, Shyr CR (2017) The genomic alterations of 5alpha-reductases and their inhibitor finasteride's effect in bladder cancer. Anticancer Res 37(12):6893–6898. https://doi.org/10.21873/anticanres.12152 CrossRefPubMed

20.

Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, Eto M (2017) Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5alpha-reductase inhibitor. J Urol 197(2):308–313. https://doi.org/10.1016/j.juro.2016.08.006 CrossRefPubMed

21.

Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, Ankerst DP, Liss MA (2016) Finasteride reduces risk of bladder cancer in a large prospective screening study. Eur Urol 69(3):407–410. https://doi.org/10.1016/j.eururo.2015.08.029 CrossRefPubMed

22.

Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K, Ueki T, Udagawa K, Kitami K, Moriyama M, Miyoshi Y, Tsuchiya F, Ikeda I, Kobayashi K, Sato M, Morita S, Noguchi K, Uemura H (2014) Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 5(24):12665–12674. https://doi.org/10.18632/oncotarget.2851 CrossRefPubMedPubMedCentral

23.

Makela VJ, Kotsar A, Tammela TL, Murtola TJ (2018) Bladder cancer survival in men using 5-alpha-reductase inhibitors. J Urol. https://doi.org/10.1016/j.juro.2018.04.082 CrossRefPubMed

24.

Taylor JA 3rd, Kuchel GA (2009) Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6(3):135–144. https://doi.org/10.1038/ncpuro1315 CrossRefPubMedPubMedCentral

25.

D'Amico AV (2011) Risk-based management of prostate cancer. N Engl J Med 365(2):169–171. https://doi.org/10.1056/NEJMe1103829 CrossRefPubMed

26.

Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99(7):558–568. https://doi.org/10.1093/jnci/djk113 CrossRefPubMed

27.

Chang C, Lee SO, Yeh S, Chang TM (2014) Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 33(25):3225–3234. https://doi.org/10.1038/onc.2013.274 CrossRefPubMed

28.

Kinoshita Y, Singh A, Rovito PM Jr, Wang CY, Haas GP (2004) Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer 3(2):83–86CrossRefPubMed

29.

Chun TY (1997) Coincidence of bladder and prostate cancer. J Urol 157(1):65–67CrossRefPubMed

30.

Vallancien G, Abou El Fettouh H, Cathelineau X, Baumert H, Fromont G, Guillonneau B (2002) Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 168(6):2413–2417. https://doi.org/10.1097/01.ju.0000036521.21034.ec CrossRefPubMed

31.

Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA (2017) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur Urol 71(6):952–960. https://doi.org/10.1016/j.eururo.2016.12.020 CrossRefPubMed

Title: Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy
Authors: Shulin Wu
Sharron X. Lin
Min Lu
Alexander O. Subtelny
Zongwei Wang
Douglas M. Dahl
Aria F. Olumi
Chin-Lee Wu
Publication date: 01-09-2019
Publisher: Springer Netherlands
Keywords: Prostate Cancer
Prostate Cancer
Androgens
Published in: International Urology and Nephrology / Issue 9/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02181-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy

Abstract

Objective

Patients and methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2019

Determining whether dexmedetomidine provides a reno-protective effect in patients receiving laparoscopic radical prostatectomy: a pilot study

Hydrogen sulfide-induced relaxation of the bladder is attenuated in spontaneously hypertensive rats

Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study

The association of preoperative reduced glomerular filtration rate with higher staging and histology grades in patients with urinary tract cancers

Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis

Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page